MIR200CHG can stimulate proliferation, invasion, and drug resistance in breast cancer by interacting with and normalizing YB-1, which is involved in regulating hypoxia-dependent gene transcription, and the hypo-phosphorylation of lactate metabolism related-signaling such as mTOR and HIF1 in cancer (56–58). The gene discussed is MTOR; the disease is breast carcinoma.